Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2017-10-11 Capital/Financing Update
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a securities purchase agreement and a registered offering of common stock. It details the terms of the offering, placement agent engagement, and includes exhibits such as the purchase agreement and engagement letter. This is a clear update on financing activities and capital raising. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a capital financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2017-10-11 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions the announcement of preliminary, unaudited financial results for the quarter ended September 30, 2017, and a registered direct offering of common stock. The document includes a press release as an exhibit. The length is 3276 characters, which is relatively short and primarily serves as an announcement rather than a full financial report. The content does not contain detailed financial statements or comprehensive analysis, but rather a summary and reference to a press release. Therefore, this filing is best classified as a Capital/Financing Update (CAP) because it includes information about a direct offering and preliminary financial results, which fits the description of updates on fundraising and financing activities.
2017-10-11 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 29, 2017, by MannKind Corporation. It reports the entry into material definitive agreements related to warrant exchange agreements and unregistered sales of equity securities. The document includes legal and transactional disclosures but does not contain financial statements or detailed financial analysis. It is a current report on material events rather than a financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2017-10-02 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically reports the resignation of a senior officer, the Chief Medical Officer, effective on a certain date. This fits the description of announcements related to changes in the company's board of directors or senior management. The document is short (2819 characters) and focuses solely on management change, not on financial results or other report types. Therefore, the appropriate classification is Board/Management Information (MANG).
2017-09-11 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 31, 2017, by MannKind Corporation. It details an amendment to a financing agreement (the Deerfield Amendment) and the deferral of payment on senior convertible notes. The content focuses on financing arrangements and amendments to existing debt agreements. There are no financial statements or comprehensive financial data presented, nor is this an announcement of a report publication. The document is a regulatory filing reporting a material event related to capital structure and financing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-09-06 English
FORM 4 SUBMISSION
Director's Dealing
2017-08-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.